Millennium Management’s Takeda Pharmaceutical TAK Stock Holding History

Millennium Management’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-97,800	Closed	-$1.52M	–	6365
2025 Q4	$1.52M	Hold	97,800	–	–	﹤0.01%	4175
2025 Q3	$1.43M	Buy	+97,800	New	+$1.45M	﹤0.01%	4338
2021 Q2	–	Sell	-89,400	Closed	-$1.63M	–	7091
2021 Q1	$1.63M	Buy	+89,400	New	+$1.61M	﹤0.01%	3725

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Millennium Management's TAK Position: Q1 2026 in Review

Millennium Management sold out of Takeda Pharmaceutical (TAK) in Q1 2026, closing a stake of 890,089 shares — an estimated $13.9M sold.

Millennium Management first reported a position in TAK in Q4 2018 and held it in 27 quarters. The position peaked at $92.7M in Q4 2023. 358 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

Millennium Management reported no remaining Takeda Pharmaceutical position as of Q1 2026 after selling out during the quarter.
Millennium Management sold 890,089 Takeda Pharmaceutical shares in Q1 2026, an estimated $13.9M.
Millennium Management first reported a position in Takeda Pharmaceutical in Q4 2018 and held it in 27 quarters.
Millennium Management's Takeda Pharmaceutical position peaked at $92.7M in Q4 2023.
358 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.